Fusion Antibodies PLC Director/PDMR Shareholding (6587M)
22 Gennaio 2021 - 4:37PM
UK Regulatory
TIDMFAB
RNS Number : 6587M
Fusion Antibodies PLC
22 January 2021
Fusion Antibodies plc
("Fusion" or the "Company")
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, has been notified that, Richard
Buick, Chief Technical Officer of the Company, has today sold 8,875
ordinary shares in the Company ("Ordinary Shares") a price of 124.2
pence per Ordinary Share. Following this sale, Richard Buick holds
486,250 Ordinary Shares, representing approximately 1.91 per cent.
of the Company's issued share capital.
The following notification, made in accordance with the
requirements of the UK Market Abuse Regulation, gives further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Buick
-------------------------- ----------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Chief Technical Officer
-------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Fusion Antibodies plc
-------------------------- ----------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
-------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies plc
type of instrument Identification code (ISIN) for Fusion
Identification code Antibodies plc ordinary shares: GB00BDQZGK16
-------------------------- ----------------------------------------------
b) Nature of the transaction Sale of shares
-------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
124.2p 8,875
----------
-------------------------- ----------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ----------------------------------------------
e) Date of the transaction 22 January 2021
-------------------------- ----------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
-------------------------- ----------------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai (Corporate
Finance)
Tony Quirke (Sales and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based biotechnology company providing a
range of antibody engineering services for the development of
antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects for its international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
Fusion is a Collaborative Research Organisation (CRO) which
provides antibody discovery, engineering and supply, through to
cell line development. At every stage, our client's vision is
central to how we work, ensuring the best molecule goes to the
clinic. Our world-class humanization and antibody optimization
platforms harness the power of the natural diversity of antibodies.
To address remaining market needs in antibody discovery, Fusion is
creating a fully human antibody library to capture the entire human
antibody repertoire.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotech companies get to
the clinic faster and ultimately speed up the drug development
process.
The global monoclonal antibody therapeutics market was valued at
$95.5 billion in 2017 and is forecast to surpass $174.2 billion in
2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to
2026. In 2018, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $62 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSEDFIEEFSEDF
(END) Dow Jones Newswires
January 22, 2021 10:37 ET (15:37 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Apr 2023 a Apr 2024